BOSTON, Oct. 5, 2023
/PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage
company focused on developing treatments for degenerative diseases
of the brain, today announced it will participate in the 2023 Roth
Healthcare Opportunities Conference on Thursday, October 12, 2023 in New York. Members of the Company's senior
management team will be presenting and hosting 1x1 meetings at the
conference.
To arrange a 1x1 meeting please email
cervomed@argotpartners.com, or contact your Roth sales team
contact. For more information about the event or questions about
registration, please contact your Roth representative.
About CervoMed
CervoMed Inc. is a clinical-stage biotechnology company
advancing CNS-focused therapeutics to benefit patients with a range
of degenerative diseases of the brain. The Company is currently
developing neflamapimod, an investigational orally administered
small molecule brain penetrant that inhibits p38MAP kinase alpha
(p38a). Neflamapimod has the potential to treat synaptic
dysfunction, the reversible aspect of the underlying
neurodegenerative processes that cause disease in dementia with
Lewy bodies (DLB) and certain other major neurological disorders.
Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB. CervoMed was
formed in August 2023 with completion
of the merger of EIP Pharma Inc. with Diffusion
Pharmaceuticals.
For more information, please visit www.cervomed.com or engage
with us on Twitter and LinkedIn.
Forward-Looking Statements
This press release includes express and implied forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, regarding the intentions, plans,
beliefs, expectations or forecasts for the future of CervoMed Inc.
(the "Company"), including, but not limited to, the therapeutic
potential of neflamapimod; anticipated milestones related to the
development of the Company's clinical programs, including timelines
for trial enrollment and reporting of data; and the potential
commercial opportunity of neflamapimod, if approved. Terms such as
"believes," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should,"
"approximately," or other words that convey uncertainty of future
events or outcomes may identify these forward-looking statements.
Although there is believed to be reasonable basis for each
forward-looking statement contained herein, forward-looking
statements by their nature involve risks and uncertainties, known
and unknown, many of which are beyond the Company's control and, as
a result, actual results could differ materially from those
expressed or implied in any forward-looking statement. Particular
risks and uncertainties include, among other things, those related
to: the Company's available cash resources and the availability of
additional funds on acceptable terms; the likelihood and timing of
any regulatory approval of neflamapimod or the nature of any
feedback the Company may receive from the U.S. Food and Drug
Administration; the Company's ability to maintain its listing on
the Nasdaq Capital Market, as well as comply with applicable Nasdaq
rules and regulations; the market price of the Company's
securities, which may be volatile due to a variety of factors,
including changes in the competitive and highly regulated industry
in which the Company operates; variations in operating performance
across competitors; changes in laws and regulations affecting the
Company's business; the ability to implement business plans,
forecasts, and other expectations in the future; general economic,
political, business, industry, and market conditions, inflationary
pressures, and geopolitical conflicts; and the other factors
discussed under the heading "Risk Factors" in the Company's most
recent Annual Report on Form 10-K, in the proxy
statement/prospectus/information statement that is included in the
Company's registration statement on Form S-4 (File No. 333-271823)
that was filed with the SEC, and other filings that the Company may
file from time to time with the SEC. Any forward-looking statements
in this press release speak only as of the date hereof (or such
earlier date as may be identified). New factors emerge from
time to time, and it is not possible for the Company to predict all
such factors, nor can we assess the impact of each such factor on
the Company's business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements.
The Company does not undertake any obligation to update such
forward-looking statements to reflect events or circumstances after
the date of this presentation, except to the extent required by
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cervomed-to-present-at-the-2023-roth-healthcare-opportunities-conference-301945841.html
SOURCE CervoMed Inc.
